• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Rapid characterization of a Delta-Omicron SARS-CoV-2 recombinant detected in Europe - Research Square. Preprint

Mary Wilson

Well-known member
Posted Date: April 4th, 2022

DOI: 10.21203/rs.3.rs-1502293/v1

Etienne SIMON-LORIERE, Xavier Montagutelli, Frederic Lemoine, Flora Donati, Franck Touret, Jerome Bourret, Matthieu Prot, Sandie Munier, Mikael Attia, Laurine Conquet, Scott Nguyen, faustine amara, Anna Maisa, Lucie Fournier, Angela Brisbarre, oceane dehan, Laurine Levillayer, Vithiagaran Gunalan, The Danish COVID-19 Genome Consortium (DCGC), Jannik Fonager, Morten Rasmussen, Stephan Kemeny, Abdelali Zrhidri, Thomas Duret, Sylvie Behillil, Vincent Enouf, Christophe Rodriguez, Slim Fourati, Jean-Michel Pawlotsky, Nicolas Capron, Hugues Leroy, Elodie Alessandri-Gradt, Florian Juszczak, Laetitia Gheysen, Véronique Brodard, Hélène Moret, Martine Bos, Matthijs Welkers, Claus Scholz, Sofia Paraskevopoulou, Laurence Josset, Claire Cervi, Brigitte Couzon, Stéphanie Marque-Juillet, Deborah Delaune, Slim El Khiari, Julien Fumey, Marie-Charlotte Hallouin-Bernard, Félix Rey, Yazdan Yazdanpanah, Bruno Coignard, Xavier de Lamballerie, Sylvie van der Werf, Axelle Paquin

Abstract

Recombination is a crucial process in the evolution of many organisms. Although the evolutionary reasons behind its occurrence in RNA viruses are debated, this phenomenon has been associated with major epidemiological events such as virus host range expansion, antigenic shift or variation in virulence 1,2, and this process occurs frequently in positive strand RNA viruses such as coronaviruses. The SARS-CoV-2 pandemic has been associated with the repeated emergence of variants of concern presenting increased transmissibility, severity or immune escape 3. The recent extensive circulation of Delta worldwide and its subsequent replacement by viruses of the Omicron lineage 4 (BA.1 then BA.2), have created conditions for genetic exchanges between viruses with both genetic diversity and phenotypic specificities 5-7. Here we report the identification and in vitro and in vivo characterization of a Delta-Omicron recombinant in Europe. This recombinant exhibits immune escape properties similar to Omicron, while its behavior in mice expressing the human ACE2 receptor is more similar to Delta. This recombinant provides a unique and natural opportunity to better understand the genotype to phenotype links in SARS-CoV-2.

https://assets.researchsquare.com/fi...f?c=1649093113
 
Back
Top Bottom